SCYNEXIS Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
16,857.00
19,024.00
257.00
257.00
257.00
257
Cost of Goods Sold (COGS) incl. D&A
16,305.00
15,446.00
-
-
-
-
Gross Income
552.00
3,578.00
-
-
-
-
SG&A Expense
8,744.00
15,476.00
27,538.00
28,048.00
26,536.00
30,187
EBIT
8,192.00
11,898.00
27,337.00
27,817.00
26,320.00
29,983
Unusual Expense
7,886.00
8,477.00
1,012.00
1,906.00
2,729.00
11,866
Non Operating Income/Expense
988.00
10.00
-
-
-
-
Interest Expense
15,371.00
803.00
-
451.00
1,855.00
2,054
Pretax Income
30,461.00
4,234.00
28,338.00
29,989.00
25,060.00
19,204
Consolidated Net Income
36,175.00
4,234.00
28,338.00
29,989.00
25,060.00
12,468
Net Income
36,175.00
4,234.00
28,338.00
29,989.00
25,060.00
12,468
Net Income After Extraordinaries
36,175.00
4,234.00
24,053.00
29,989.00
25,060.00
12,468
Net Income Available to Common
46,809.00
5,867.00
32,550.00
29,989.00
25,060.00
12,468
EPS (Basic)
139.47
1.04
2.68
1.58
0.94
0.28
Basic Shares Outstanding
1,581.30
5,663.30
12,163.60
19,035.30
26,746.30
43,884
EPS (Diluted)
29.60
2.69
2.68
1.58
0.94
0.28
Diluted Shares Outstanding
1,581.30
5,937.10
12,163.60
19,035.30
26,746.30
43,884
EBITDA
6,863.00
10,660.00
27,281.00
27,791.00
26,279.00
29,930
Non-Operating Interest Income
-
-
11.00
185.00
386.00
967
Other After Tax Income (Expense)
5,714.00
-
-
-
-
-
Preferred Dividends
10,634.00
1,633.00
-
-
-
-

About SCYNEXIS

View Profile
Address
1 Evertrust Plaza
Jersey City New Jersey 07302
United States
Employees -
Website http://www.scynexis.com
Updated 07/08/2019
SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.